Clinical Trial Update: Ixazomib Rollover Study [Phase 2]

View source ↗

Summary

A Phase 2 Ixazomib rollover study has completed, with results posted on 2025-03-12. The study encompassed multiple myeloma, lymphoma, and amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis
• Lymphoma
• Multiple Myeloma

Drugs mentioned

• ixazomib (ixazomib)

Snippet

Sponsor: Takeda | Conditions: Multiple Myeloma, Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2025-03-12